The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly (LLY-0.12%) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in the U.S. in ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Eli Lilly weight loss drug beat Wegovy in a head-to-head clinical trial — 20.2% body weight loss on Zepbound compared to 13.7% on Novo Nordisk obesity drug. Skip to Main Content.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable safety profile.

Eli Lilly (NYSE:LLY) said Wednesday its weight-loss drug Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Danish rival Novo Nordisk’s Wegovy (semaglutide) in the ...

Eli Lilly and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in the U.S. in 2021, has ...